| Literature DB >> 26457177 |
Jing Su1, Carl Ekman2, Nikolay Oskolkov2, Leo Lahti3, Kristoffer Ström2,4, Alvis Brazma1, Leif Groop2, Johan Rung1,5, Ola Hansson2.
Abstract
BACKGROUND: Although high-throughput studies of gene expression have generated large amounts of data, most of which is freely available in public archives, the use of this valuable resource is limited by computational complications and non-homogenous annotation. To address these issues, we have performed a complete re-annotation of public microarray data from human skeletal muscle biopsies and constructed a muscle expression compendium consisting of nearly 3000 samples. The created muscle compendium is a publicly available resource including all curated annotation. Using this data set, we aimed to elucidate the molecular mechanism of muscle aging and to describe how physical exercise may alleviate negative physiological effects.Entities:
Keywords: Aging; Exercise; Expression; Microarray; Mitochondrial dysfunction; Skeletal muscle
Year: 2015 PMID: 26457177 PMCID: PMC4600214 DOI: 10.1186/s13395-015-0059-1
Source DB: PubMed Journal: Skelet Muscle ISSN: 2044-5040 Impact factor: 4.912
Defined terms and value ranges used to annotate the compendium
| Parameter | Value | Arrays |
|---|---|---|
| Sex | Male | 1085 |
| Female | 691 | |
| Mixed | 443 | |
| Unknown | 85 | |
| Age | Age given | 993 |
| Age group | 642 | |
| Age range | 518 | |
| Unknown age | 151 | |
| T2D status | Non-T2D | 1269 |
| NGT | 321 | |
| IGT | 86 | |
| IGT or T2D | 89 | |
| T2D | 124 | |
| Unknown | 415 | |
| BMI | BMI given | 207 |
| BMI group | 637 | |
| BMI unknown | 1460 | |
| Physical capacity | PC given | 175 |
| PC group | 81 | |
| PC unknown | 2048 | |
| Family history of diabetes | FH+ | 24 |
| FH− | 159 | |
| FH unknown | 2121 | |
| Muscle type | Quad | 1970 |
| Other muscle | 242 | |
| Unknown | 92 | |
| Interventions | Clamp | 316 |
| Longer training | 158 | |
| Shorter training/damage | 213 | |
| Immobilization 2 days | 72 | |
| Immobilization 4–14 days | 100 | |
| Immobilization 60 days | 170 | |
| Protein intake | 88 | |
| Other | 196 | |
| Immobilized/trained | Trained | 108 |
| Immobilized | 175 | |
| Acute trained >24 h | 106 |
2852 samples were annotated. As far as possible, exact values were recorded for numerical parameters. For some studies, individual records were not resolvable, and instead a group average and dispersion measure was given
T2D type 2 diabetes
Top 50 genes significantly associated with age across 361 samples
| Gene | Min ( | Max |β| |
|---|---|---|
| H3F3B | 3.39E-13 | 0.0098 |
| AHNAK | 6.87E-12 | 0.0086 |
| HOXB2 | 1.01E-11 | −0.0184 |
| CRIM1 | 5.34E-11 | 0.0124 |
| NAP1L1P3 | 9.74E-11 | 0.0154 |
| ARFGAP2 | 3.56E-10 | 0.0069 |
| WDR6 | 4.47E-10 | 0.0069 |
| DLEU1 | 8.61E-10 | −0.0117 |
| USP6 | 1.43E-09 | 0.0133 |
| TCF25 | 2.70E-09 | 0.0064 |
| SCN4B | 3.13E-09 | −0.0289 |
| ZNF274 | 3.87E-09 | 0.0129 |
| HDAC4 | 4.04E-09 | 0.0155 |
| SH3BP5 | 5.04E-09 | 0.0114 |
| SART3 | 5.32E-09 | 0.0050 |
| CASC3 | 9.73E-09 | 0.0061 |
| CIRBP | 1.14E-08 | 0.0091 |
| HIST1H2BN | 1.49E-08 | −0.0065 |
| FUBP1 | 1.74E-08 | 0.0058 |
| FAM171A1 | 1.94E-08 | −0.0113 |
| NPPA | 1.97E-08 | −0.0048 |
| TMEM59L | 2.39E-08 | −0.0080 |
| UBE2O | 2.79E-08 | −0.0060 |
| FEZ2 | 2.83E-08 | 0.0126 |
| ALS2CL | 3.15E-08 | −0.0063 |
| C1S | 3.22E-08 | 0.0137 |
| RXRG | 3.23E-08 | −0.0095 |
| NT5C2 | 3.64E-08 | 0.0115 |
| TRMT112 | 4.42E-08 | 0.0116 |
| PRNP | 4.68E-08 | 0.0094 |
| NOL9 | 6.31E-08 | 0.0049 |
| RBM10 | 6.66E-08 | 0.0056 |
| ANP32B | 6.71E-08 | 0.0092 |
| TOMM40L | 6.74E-08 | −0.0144 |
| HTR5A | 7.21E-08 | −0.0051 |
| SEC24C | 7.78E-08 | 0.0060 |
| BUB3 | 7.98E-08 | 0.0036 |
| DAAM2 | 8.92E-08 | −0.0091 |
| HSPA1A | 8.93E-08 | 0.0091 |
| SEZ6L2 | 9.12E-08 | −0.0046 |
| MRPL4 | 9.38E-08 | −0.0080 |
| CMC2 | 1.04E-07 | −0.0091 |
| NR1D1 | 1.04E-07 | −0.0054 |
| ENDOG | 1.11E-07 | −0.0126 |
| MRPL48 | 1.25E-07 | −0.0066 |
| FRAT2 | 1.31E-07 | −0.0064 |
| SYNRG | 1.31E-07 | 0.0040 |
| PPIC | 1.38E-07 | −0.0076 |
| POMT1 | 1.47E-07 | 0.0061 |
| DECR2 | 1.65E-07 | 0.0043 |
The minimum p and maximum β values were calculated for genes present in both array datasets, adjusted for sex and study effect. A positive β value implicates increasing gene expression with age. For the full list of 957 genes, see Table S2 in Additional file 2
Fig. 1Principal component analysis of the 211 HG-U133A arrays, before (a) and after (b) removal of study effects and corresponding plots for the 150 HG-U133 + 2 arrays (c and d). Different studies (identified by database accession numbers) are represented with different colors, and increasing age of the individual from whom the biopsy was taken is indicated by the increasing dot size. The relatively strong study effect seen even after normalization is removed after the adjustment
Gene set enrichment analysis for the 484 genes upregulated with age and the 473 downregulated
| Upregulated sets | ES | NES | FDR |
|---|---|---|---|
| KEGG_COMPLEMENT_AND_COAGULATION_CASCADES | 0.80 | 2.32 | 0.0047 |
| REACTOME_INITIAL_TRIGGERING_OF_COMPLEMENT | 0.89 | 2.18 | 0.0133 |
| REACTOME_COMPLEMENT_CASCADE | 0.89 | 2.15 | 0.0138 |
| BIOCARTA_COMP_PATHWAY | 0.86 | 2.21 | 0.0148 |
| KEGG_SYSTEMIC_LUPUS_ERYTHEMATOSUS | 0.75 | 2.07 | 0.0288 |
| BIOCARTA_CLASSIC_PATHWAY | 0.90 | 2.04 | 0.0361 |
| Downregulated sets | |||
| REACTOME_TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT | −0.76 | −2.90 | 0.0000 |
| MITOCHONDRION | −0.59 | −2.70 | 0.0000 |
| REACTOME_PYRUVATE_METABOLISM_AND_CITRIC_ACID_TCA_CYCLE | −0.81 | −2.48 | 0.0008 |
| MITOCHONDRIAL_ENVELOPE | −0.74 | −2.39 | 0.0010 |
| MITOCHONDRIAL_MEMBRANE | −0.74 | −2.37 | 0.0011 |
| MITOCHONDRIAL_PART | −0.74 | −2.39 | 0.0012 |
| KEGG_PARKINSONS_DISEASE | −0.73 | −2.40 | 0.0013 |
| ORGANELLE_INNER_MEMBRANE | −0.74 | −2.30 | 0.0014 |
| ORGANELLE_ENVELOPE | −0.68 | −2.33 | 0.0015 |
| MITOCHONDRIAL_INNER_MEMBRANE | −0.74 | −2.30 | 0.0015 |
| ENVELOPE | −0.68 | −2.26 | 0.0019 |
| KEGG_OXIDATIVE_PHOSPHORYLATION | −0.64 | −2.23 | 0.0024 |
| REACTOME_PYRUVATE_METABOLISM | −0.81 | −2.22 | 0.0025 |
| COFACTOR_METABOLIC_PROCESS | −0.69 | −2.19 | 0.0037 |
| KEGG_ALZHEIMERS_DISEASE | −0.60 | −2.07 | 0.0117 |
| MITOCHONDRIAL_MEMBRANE_PART | −0.74 | −2.08 | 0.0123 |
| REACTOME_RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMIOSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_PROTEINS_ | −0.70 | −2.02 | 0.0161 |
| REACTOME_GLUCOSE_METABOLISM | −0.70 | −2.03 | 0.0162 |
| REACTOME_GLUCONEOGENESIS | −0.77 | −2.01 | 0.0187 |
| ION_TRANSPORT | −0.82 | −1.99 | 0.0199 |
| COENZYME_METABOLIC_PROCESS | −0.82 | −2.00 | 0.0200 |
| REACTOME_REGULATION_OF_PYRUVATE_DEHYDROGENASE_PDH_COMPLEX | −0.81 | −1.96 | 0.0246 |
| HYDROGEN_ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | −0.78 | −1.94 | 0.0283 |
| INORGANIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | −0.78 | −1.91 | 0.0340 |
| ION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | −0.50 | −1.90 | 0.0378 |
| MONOVALENT_INORGANIC_CATION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY | −0.78 | −1.89 | 0.0380 |
| KEGG_CITRATE_CYCLE_TCA_CYCLE | −0.77 | −1.89 | 0.0385 |
Thirty-nine genes genome-wide significantly associated with physical capacity across 116 samples
| Gene | Min ( | Max |β| |
|---|---|---|
| SOCS2 | 6.28E-08 | 0.014 |
| SLC16A10 | 8.53E-07 | −0.024 |
| HOMER1 | 1.02E-06 | −0.018 |
| ZMYND17 | 1.84E-06 | −0.021 |
| BCKDHB | 3.06E-06 | 0.010 |
| INADL | 4.99E-06 | −0.011 |
| MAST2 | 5.28E-06 | −0.011 |
| BDH1 | 5.76E-06 | 0.015 |
| ZNF133 | 6.37E-06 | −0.008 |
| METTL7A | 1.22E-05 | −0.022 |
| ZNF57 | 1.30E-05 | 0.011 |
| TMEM56 | 1.61E-05 | −0.021 |
| RALGAPA1 | 1.66E-05 | −0.010 |
| CALU | 1.89E-05 | 0.009 |
| SYNPO2L | 2.11E-05 | −0.014 |
| RP11-304 L19.5.1 | 2.33E-05 | −0.018 |
| AQP1 | 2.79E-05 | 0.014 |
| SCPEP1 | 2.96E-05 | −0.014 |
| KIAA1109 | 3.02E-05 | 0.004 |
| HYI | 3.46E-05 | −0.008 |
| FEZ2 | 3.46E-05 | −0.020 |
| EIF4E2 | 3.79E-05 | −0.016 |
| LPL | 3.85E-05 | 0.028 |
| ZNRF1 | 3.89E-05 | −0.010 |
| YPEL2 | 3.98E-05 | −0.013 |
| DMRT2 | 4.37E-05 | 0.019 |
| UGGT1 | 4.61E-05 | −0.007 |
| MPP7 | 4.79E-05 | 0.012 |
| SUN1 | 5.37E-05 | −0.008 |
| BRD8 | 5.77E-05 | −0.008 |
| PRKAG3 | 6.04E-05 | −0.025 |
| SLC38A1 | 6.10E-05 | 0.047 |
| ITGA6 | 6.32E-05 | 0.018 |
| CMBL | 6.74E-05 | −0.011 |
| NANOS1 | 8.65E-05 | −0.035 |
| SCGB1D2 | 8.80E-05 | 0.027 |
| MESP1 | 8.97E-05 | −0.008 |
| HSPA2 | 9.31E-05 | −0.022 |
| HEMK1 | 9.56E-05 | −0.008 |
A positive β value implicates increasing gene expression with increased physical capacity, adjusted for study effect
Of the 957 aging genes, 21 were significantly associated with physical capacity across 116 samples
| Gene |
|
|
|
|
|---|---|---|---|---|
| SOCS2 | 5.51E-07 | 6.28E-08 | −0.0034 | 0.0143 |
| SLC16A10 | 0.000785 | 8.53E-07 | 0.00354 | −0.02369 |
| METTL7A | 0.001265 | 1.22E-05 | 0.011168 | −0.02183 |
| CALU | 0.00086 | 1.89E-05 | −0.00311 | 0.009051 |
| FEZ2 | 2.83E-08 | 3.46E-05 | 0.012589 | −0.01958 |
| DMRT2 | 0.000223 | 4.37E-05 | −0.01035 | 0.018518 |
| ITGA6 | 0.000564 | 6.32E-05 | −0.00607 | 0.017743 |
| MESP1 | 0.000246 | 8.97E-05 | −0.00638 | −0.00767 |
| IP6K2 | 2.32E-06 | 0.000112 | 0.005743 | −0.00807 |
| ANKRD27 | 0.000118 | 0.000121 | 0.006005 | −0.02111 |
| MPC1 | 0.000705 | 0.000148 | −0.00478 | 0.010666 |
| PAF1 | 1.07E-06 | 0.000258 | 0.006852 | −0.01292 |
| SLIT2 | 0.000698 | 0.000297 | 0.009127 | −0.01342 |
| DDX24 | 2.01E-05 | 0.000318 | 0.004313 | −0.00869 |
| FAM53C | 0.001351 | 0.000342 | 0.003416 | −0.00845 |
| CPSF7 | 0.000491 | 0.000405 | 0.003669 | −0.00789 |
| DGKD | 0.000456 | 0.000838 | 0.00429 | −0.01153 |
| PHF20 | 0.001338 | 0.000871 | 0.00284 | −0.00665 |
| ABRA | 0.001011 | 0.000952 | 0.014313 | −0.01971 |
| NT5C2 | 3.64E-08 | 0.000954 | 0.011521 | −0.01262 |
| DNAJB2 | 9.22E-07 | 0.000956 | 0.007196 | −0.01217 |
A positive β value implicates increasing gene expression with increased physical capacity, adjusted for study effect
Fig. 2Expression levels of SOCS2 (a), FEZ2 (b), MPC1 (c), and NT5C2 (d) in relation to age. Batch effect-adjusted expression levels are shown
Of the 957 aging genes, three were associated with type 2 diabetes
| Gene |
|
|
|
|
|---|---|---|---|---|
| CD163 | 0.00022 | 0.000195 | 0.009341 | 3.725788 |
| ZNF415 | 8.93E-05 | 8.49E-05 | −0.01078 | −3.9301 |
| GADD45A | 0.000541 | 0.000112 | 0.011251 | 3.862089 |
Analysis of 102 samples with type 2 diabetes (T2D) versus 87 normoglycemic individuals. A positive Z value implicates increasing gene expression with T2D, adjusted for study effect
Fig. 3Schematic illustration of major metabolic effects of aging in human skeletal muscle. A subjectively selected set of effector and regulatory genes from the 957 age-associated genes are shown with their direction of regulation shown with respect to increasing age